REFERENCES
- Stinchcombe T, Choi J, Schell M, Mears A, Jones P, Nachtsheim R, et al. Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor PS. Lung Cancer 2006; 51: 237–243.
- Putnam JS. Lung carcinoma in young adults. JAMA 1977; 238: 35–6.
- DeCaro L, Beneld JR. Lung cancer in young persons. J. Thorac Cardiovasc Surg 1982; 8: 372–6.
- Awadh-Behbehani N, Al-Humood K, Ayed A, Memon A, Ali A. Comparison between young and old patients with bron-chogenic carcinoma. Acta Oncologica 2000; 39: 995–999.
- Kyriakos M, Webber B. Cancer of the lung in young men. J Thorac Cardiovasc Surg 1974; 67: 634–7
- Mauri D, Pentheroudakis G, Bafaloukos D, Pectasides D, Samantas E, Efstathiou E, et al, Hellenic Cooperative Oncologic Group (HeCOG). Non-small cell lung cancer in the young: a ret-rospective analysis of diagnosis, management and outcome data. Anticancer Res 2006; 26 :3175-81
- Bourke W, Milstein D, Giura R, Donghi M, Luisetti M, Rubin AH, et al. Lung cancer in young adults. Chest 1992; 102: 1723–9
- Tse LA, Yu IT, Au JS, Yu KS, Kwok KP, Qiu H, et al. En-vironmental tobacco smoke and lung cancer among Chinese nonsmoking males: might adenocarcinoma be the culprit? Am J Epidemiol. 2009; 169: 533-41.
- Chen F, Jackson H, Bina WF. Lung adenocarcinoma inci-dence rates and their relation to motor vehicle density. Cancer Epidemiol Biomarkers Prey. 2009; 18: 760–4.
- Quoix E. Novel epidemiology in lung cancer - non-smok-ers, women and cannabis. Rev Mal Respir. 2007; 24 (8 Pt 2): 6 S10-5.
- Andresen O, Sorenson S, Bergman B, et al. Duration of chemotherapy and survival in advanced non-small cell lung can-cer (NSCLC): a multicenter, prospective randomized study [ab-stract]. Lung Cancer 2003; 41: 528
- Smith 1E, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a ran-domized trial of three versus six courses of mitomycin, vinblas-tine, and cisplatin. J Clin Oncol 2001; 19: 1336–1343
- Yazgan S, Gursoy S, Yaldiz S, Basok 0. Outcome of sur-gery for lung cancer in young and elderly patients. Surg Today 2005; 35: 823–7
- Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980; 65: 25–32
- Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Sur-vival determinants in extensive-stage non small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991 ; 9: 1618–26
- Borges M, Sculier JP, Paesmans M, et al. Prognostic factors for response to chemotherapy containing platinum deriva-tives in patients with unresectable non-small cell lung cancer (NSCLC). Lung Cancer 1996; 16: 21–33
- Kelly K. Challenges in defining and identifying patients with non-small cell lung cancer and poor performance status. Semin Oncol 2004; 31: 3–7
- Lilenbaum R, Herndon J, List MG et al. Single-agent ver-sus combination chemotherapy in advanced non-small cell lung cancer: a CALGB randomized trial of efficacy, quality of life and cost-effectiveness. Proc Am Soc Clin Oncol 2002; 21:1a
- Costa GJ, Godoy Fernandes AL, Pereira JR, J Curtis R, Santoro IL. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC). Lung Cancer. 2006; 53: 171–6.
- Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, et al. Outcomes for elderly, advanced stage non small cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008; 26: 60–65.
- Raez L, Lilenbaum R. New developments in chemother-apy for advanced non-small cell lung cancer. Curr Opin Oncol 2006; 18: 156–161